Fig. 6

Pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) with PJ34 attenuates liver inflammation in R778L mice. (A) Representative image showing immunofluorescence staining for Ly6G in the livers of R778L and wild-type (WT) mice following PJ34 or vehicle treatment. (B) Quantification of lymphocyte antigen 6G (Ly6G)-positive cells per field in the livers of R778L and WT mice following PJ34 or vehicle treatment (n = 6–8 per group). (C) Quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) analysis of Tnf, Il1b, and Il66 mRNA expression in livers of R778L and WT mice following PJ34 or vehicle treatment (n = 5–9 per group). The data are presented as the mean ± SEM and were evaluated using two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. *** p < 0.001 versus the mice treated with vehicle